### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### **Current Report**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2021 (January 14, 2021)

### MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

001-31719

Delaware (State or other jurisdiction of incorporation)

(Commission File Number)

13-4204626

(IRS Employer Identification No.)

200 Oceangate, Suite 100, Long Beach, California 90802 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (562) 435-3666

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 Par Value	МОН	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.

#### Item 7.01. Regulation FD Disclosure.

On Thursday, January 14, 2021, the Company's management held a virtual presentation and question and answer session at the 39th Annual J.P. Morgan Healthcare Conference. A copy of the Company's complete slide presentation is included as Exhibit 99.1 to this report. An audio and slide replay of the Company's presentation will be available for 30 days from the date of the presentation on the Company's website www.molinahealthcare.com.

Note: The information furnished herewith pursuant to Item 7.01 of this current report on Form 8-K shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits.

#### (d) Exhibits:

Exhibit	
No.	Description
<u>99.1</u>	Slide presentation in connection with the Company's presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021.
104	Cover page information from Molina Healthcare, Inc.'s Current Report on Form 8-K filed on January 14, 2021 formatted in iXBRL (Inline Extensible Business Reporting Language)

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### MOLINA HEALTHCARE, INC.

Date: January 14, 2021

By: /s/ Jeff D. Barlow

Jeff D. Barlow, Chief Legal Officer and Secretary



## Molina Healthcare, Inc. JP Morgan Healthcare Conference

Joe Zubretsky, President and Chief Executive Officer

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This presentation and the accompanying oral remarks include forward-looking statements regarding, without limitation, the Company's strategic position, its projected 2021 premium revenues and future revenue growth prospects, political and judicial developments, the continuing impacts of the COVID-19 pandemic during 2021, Medicaid rates and risk corridor provisions, and our 2021 Marketplace business and membership. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company cannot guarantee that it will actually achieve the plans, outlook, or expectations disclosed in its forward-looking statements and, accordingly, you should not place undue reliance on the Company's forward-looking statements. Those risks and uncertainties are discussed under Item 1A in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K and also in the Company's quarterly reports and other reports and filings with the Securities and Exchange Commission, or SEC. These reports can be accessed under the investor relations tab of the Company's website or on the SEC's website at www.sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that the results or events projected or contemplated by its forward-looking statements will in fact occur. All forward-looking statements in this presentation represent management's judgment as of January 14, 2021, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statements to conform the statement to actual results or changes in its expectations.

# Today's Agenda

Compelling Strategic Position4Q20 First Glimpse2020 Full Year Performance2021 Initial Outlook

## **Compelling Strategic Position**

Despite pandemic, business remains resilient and strategy unchanged

Operating Metrics	<ul> <li>Focused on managed care fundamentals</li> <li>Maintain industry leading margin position</li> <li>Generate significant excess cash flow and capital</li> </ul>
Growth Strategy	<ul> <li>Grow premium revenue ~13% and ~25% in 2020 and 2021, respectively</li> <li>Organic growth opportunities remain compelling</li> <li>Expert acquisition team, disciplined approach</li> </ul>
Business Environment	<ul> <li>Democrats control Congress and The White House</li> <li>SCOTUS threat diminished</li> <li>Support for Medicaid expansion and Marketplace subsidies</li> </ul>
	4

## **Molina's Footprint Expanded in 2020**

Checked the box on all aspects of our growth strategy initiatives in 2020 despite the global pandemic



# 4Q20 First Glimpse & 2020 Full Year Performance



## 4Q20 First Glimpse

Normalized performance continues to be strong and in line with previous expectations



Strong normalized performance, excluding the net impact of COVID and a one-time item, continues with 4Q projected to be  $\sim$ \$3.00 per share



Quarter impacted by recently enacted COVID risk sharing corridors, likely to be a net decrease to 4Q earnings of (~\$3.50) per share



One-time non-recurring items yield a benefit of ~\$1.00 per share

### 2020 Full Year Performance

2020 full year normalized earnings; continued strong performance



Normalized performance projected to exceed full year GAAP guidance of \$11.20 – \$11.70 per share




Net negative impact of COVID (~\$2.00) per share



Positive benefit from one-time non-recurring items of ~\$1.00 per share



# 2021 Initial Outlook



## **2021 Medicaid Rate Environment**

Modest challenges from temporary COVID risk sharing corridors but actuarial soundness preserves outlook for margins

Core Rates	<ul> <li>Known on 85% of revenue</li> <li>Average increase of ~1.7%</li> <li>Some states assumed COVID-related utilization suppression</li> <li>Rates reflect cost trend and are actuarily sound</li> </ul>
COVID Risk Sharing Corridors	<ul> <li>Many COVID risk sharing corridors extend into 2021</li> <li>COVID risk sharing corridors are expected to be temporary</li> <li>2020 corridors enacted retrospectively</li> <li>2021 corridors enacted prospectively, providing greater visibility</li> </ul>

## 2021 Marketplace Update

Improved outlook in 2021 driven by enhanced operating performance



## **2021 Initial Premium Revenue Outlook**

Continued execution of growth strategy leads to 2021 premium revenue of over \$23 billion, or ~25% increase over 2020



## 2021 Outlook

### Durable earnings catalysts largely mitigate temporary earnings challenges



### Catalysts

- Strong normalized performance in Medicaid and Medicare
- · Marketplace margin recovery and growth
- · Continued COVID-related utilization suppression
- HIF elimination
- Accretion of MCC



### Challenges

- COVID risk sharing corridors
- COVID medical costs
- Resumption of membership redetermination
- Medicare risk adjustment
- Rx carve-outs

## **Compelling Strategic Position**

Despite pandemic, business remains resilient and strategy unchanged



# **Questions and Answers**

